MBX Biosciences Announces Q3 EPS of 63c, Below Consensus Estimate of 66c
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 06 2025
0mins
Positive Trial Results: MBX Biosciences reported successful topline results from their Phase 2 Avail trial of canvuparatide, indicating its potential as a leading treatment for hypoparathyroidism.
Market Potential: The company believes canvuparatide could dominate a multibillion-dollar market, highlighting its strategic importance in their pipeline.
Regulatory and Trial Preparations: MBX is preparing for meetings with US and EU regulatory agencies and plans to initiate a Phase 3 trial, signaling progress towards commercialization.
Strong Financial Position: With a validated PEP(TM) platform and funding secured until 2029, MBX is positioned to achieve key milestones in 2026 and aims to become a leading biopharma company in endocrine and metabolic diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MBX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MBX
Wall Street analysts forecast MBX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBX is 59.33 USD with a low forecast of 31.97 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
7 Buy
0 Hold
1 Sell
Strong Buy
Current: 36.840
Low
31.97
Averages
59.33
High
80.00
Current: 36.840
Low
31.97
Averages
59.33
High
80.00
About MBX
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. It has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analyst Target Prices Indicate Potential for Pharmaceuticals ETF
- ETF Upside Potential: The iShares U.S. Pharmaceuticals ETF (IHE) has an implied analyst target price of $96.28 per unit, while trading at $86.15, indicating an 11.76% upside, reflecting market optimism about the ETF's future performance.
- MBX Stock Analysis: MBX BIOSCIENCES INC (MBX) trades at $35.83, with an analyst target price of $60.55, suggesting a potential upside of 69.01%, showcasing investor confidence in its future prospects.
- CRNX Stock Outlook: Crinetics Pharmaceuticals Inc (CRNX) has a current price of $51.32 and an analyst target of $83.46, indicating a 62.63% upside, reflecting positive market sentiment regarding its product and R&D advancements.
- XERS Investment Opportunity: Xeris Biopharma Holdings Inc (XERS) is priced at $7.14, with an analyst target of $11.14, showing a 56.05% upside, indicating analysts' optimism about its growth potential.
Continue Reading
MBX Biosciences Advances Obesity Drug Development with Strong Cash Position
- Clinical Trial Progress: MBX's Phase 2 trial demonstrated significant efficacy of canvuparatide in chronic hypoparathyroidism patients, with one-year follow-up data expected in Q2 2026, reinforcing its potential as a best-in-class therapy.
- Obesity Drug Pipeline Expansion: Data from MBX 4291, a dual GLP-1/GIP co-agonist, is anticipated in Q4 2026, showcasing potential for once-monthly dosing aimed at improving tolerability for obesity patients, addressing a critical market need.
- Strong Cash Position: As of December 31, 2025, MBX reported approximately $373.7 million in cash and equivalents, expected to fund operations into 2029, ensuring continued investment in R&D and market expansion.
- New Candidate Nominations: In 2026, MBX plans to nominate two additional obesity candidates, an amycretin prodrug and a GLP-1/GIP/GCGR triple agonist, each designed for once-monthly dosing, further enriching its obesity treatment pipeline.
Continue Reading